PHARMA LITERATI

We announced about IP(harma)L 2016 - Indian Pharma League 2016 at  http://pharmaliterati.blogspot.in/2016/04/ipharmal-2016-indian-pharma-league-2016.html We start our league with  NIPER, Mohali.  NIPER Mohali has been leading the Indian pharmacy academia since its inception.   It is one of the most vibrant places to be at in the pharma academia. Be it conferences, seminars, workshops, training programs, any other events or anything; NIPER, Mohali has created its own culture on its own. National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as   an 'Institute of National Importance '. It is an autonomous body set up under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and...

We at pharma literati started many initiatives for our readers and the students. Many of them worked and few did not. In a time, when it is really very difficult to sustain in this area because of lack of time and motivation to keep going, we continued our efforts to establish the brand pharma literati.   In the journey of eighteen months many bloggers joined us and left to pursue their higher studies or careers including some founder members of the blog. This has resulted in lesser number of posts for the blog and stagnancy in terms of the subscribers. As a part of our continuous endeavours to provide pharma related knowledge to all our readers and students across India, we are starting an initiative called "Earn while you learn". The students and the faculty members are encouraged to join us as bloggers and we would pay them based on the number of posts and the activities they are involved in. Activities: 1.  ...

Let’s continue our series of Future of Drugs. We are now going to take you through the new drugs that are being developed and those that might actually get approved against the rising incidence of Heart Diseases and Stroke. Ciraparantag has tremendous potential of competing with anticoagulants like edoxaban, rivaroxaban, dabigatran and apixaban. Ciraparantag is to be administered IV.  Drug Name Ciraparantag Structure   Drug Code PER 977 Synonym Aripazine N,N'-(1,4-piperazinediyldi-3,1-propanediyl)bis[2-amino-5-[(aminoiminomethyl)amino]-, (2S,2'S)-pentanamide Molecular Formula C 22 H 48 N 12 O 2 Innovator Perosphere Condition Anticoagulant Reversal Mechanism of Action Blood coagulation factor modulators; Factor Xa inhibitors Clinical Phase II in USA (Fast Track Designation)   ...

UK-based Pharma Compa ny GlaxoSmithKline and one of the oldest pharma MNC in India, has announced that it will not file for patents in the low income countries . In other words, it will allow companies to make copycat generic drugs in these markets, either without paying any royalty to them or with a small royalty fee. GSK is not the sole pharma company to make such a move, earlier global pharma majors Merck and Roche too had made similar announcements. What do moves such as these mean for global pharma majors and what will it mean for India? For the global pharma majors, these markets (low income countries)  typically do not contribute much financially so it is unlikely to mean anything significant to their bottomline but it would be according to critics "a good move that showcases their human face." As for India, it does not mean much to the patients here as the country has outgrown this status so the MNCs will continue to file patents in India. It is therefor...

The Narendra Modi government has come in for sharp criticism from some in the Indian pharmaceuticals industry over its policy on the production of generic drugs in India that has been perceived as favouring U.S. drugmakers over Indian ones, and as being directly contradictory to the prime minister's Make in India campaign. Lee Pharma, a Hyderabad-based mid-sized drug company, said Thursday that the Drug Controller General of India (DCGI) did not allow it to sell cheaper and generic versions of a diabetic drug possibly due to the Modi government's assurance to U.S. pharma companies over the issue of protecting intellectual property rights (IPRs). The company had applied for a compulsory licence from the DCGI last year to produce a cheaper, generic version of the diabetes medicine saxagliptin, made by global pharma firm AstraZeneca. "The DCGI rejected our application for the second time this year although we covered all the necessary grounds made mandatory by the d...

A 24-year woman student pursuing her masters in pharmacy from Pune based college has been duped by unidentified suspects on the pretext of getting her job with a leading pharmaceutical compan y. The woman was contacted over her email address and was made to deposit Rs 10, 000 in a bank account with a nationalised bank for getting the job. Anil Chintaman Rajurkar (55) a resident of Mehernagar, Garkheda has complained to the Cidco police station that his daughter Anushri (24) is doing M Pharm in a Pune college and received an e-mail informing her about her selection in Ranbaxy Laboratories New Delhi and asked her to deposit the money in Punjab National Bank account. On her request he deposited the amount in the given account of the bank. Anushri kept waiting for response for days together but in vain. Rajurkar stated that whenever she contacted the suspects to inquire about the job they promised, they would enquire whether she has deposited the money and even started seeking ...

We have so many students abroad studying Pharmacy or working. Students in India always wonder about how the situation might be abroad. We always assume that it might be way better. But as word of mouth has to be believed, the situation abroad is similar to that back home. Let’s get the confusion cleared up a bit! We would like to invite many such students to share their experiences with us about studying abroad/ working abroad. Just drop us a mail at pharmaliterati@gmail.com  and we will get back to you with a questionnaire to make your life easy. Please note that confidentiality will be maintained if you don’t want your name on this blog. But if you ask us, this is a wonderful opportunity for your opinions to be heard!